Shares of Bristol Myers Squibb Co. BMY rose 1.39% to $59.62 Friday, on what proved to be an all-around positive trading ...

It was a big month for retirements, with AMC Entertainment and Bristol Myers Squibb both announcing planned exits for ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 ---- IND-enabling studies ongoing for PM577 for ...

Four top stocks have at least a 4% dividend and make sense for investors who may be worried about increased volatility in the ...

Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 13.7%. Its stock price has climbed to $58.28, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and ...

Oppenheimer & Co. Inc. reduced its stake in Bristol-Myers Squibb by 8.1%, selling nearly 19,000 shares in Q4. The ...

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.

Mary-Claire King, a groundbreaking innovator in genetics, received The National Academy of Sciences' most prestigious metal.